Business Wire

MACIF’s Successful Euro 1,75 bn Issuance Attracted Huge Appetite From European Investors

Share

MACIF, Aéma Groupe’s affiliate, announces the successful issuance of a multi-tranche €1.75bn subordinated debt issuance comprising:

- a €400mn Perpetual Non-Call 2029 Restricted Tier 1 fixed resettable rate notes bearing interest at an initial fixed rate of 3.50% until the first call date and expected to be rated Ba1 by Moody’s
- a €850mn 2052 Non-Call 2032 Tier 2 fixed to floating rate notes bearing interest at an initial fixed rate of 2.125% until the first call date and expected to be rated Baa1 by Moody’s
- a €500mn 2027 Tier 3 notes bearing interest at a 0.625% fixed rate coupon and expected to be rated Baa1 by Moody’s

MACIF has met with over 85 institutional investors over phone calls which took place from 8th to 11th June 2021 in order to present the Group’s credit. With more than 400 investors participating into the multi-tranche transaction for a total book size over €12.1bn, this represents the first Euro triple-tranche subordinated from a European insurer.

The three days of virtual roadshow conducted as part of this capital increase have again proved the great appetite of investors towards Macif's solid business model.

These transactions constitute a significant part of Aviva France’s acquisition financing and the proceeds of the notes will be eligible for inclusion in Solvency II regulatory capital, reinforcing the newly formed Group capital base.

Credit Suisse acted as Structuring Advisor and Global Coordinator, HSBC and Natixis acted Global Coordinators and BBVA, BNP Paribas, JP Morgan, ING, RBC and Société Générale acted as Joint Lead Managers on these transactions.

About Aéma Groupe
Aéma Groupe is the mutual protection group resulting from the merger between Aésio and Macif.
With 8 million policy-holders, it employs 14,000 people and has a turnover of 8 billion euros in France.
Every day, Aéma Groupe imagines the outlines of a fairer and more humane world by placing thoughtfulness at the heart of its relationship with its members, shareholders and corporate clients..
Find out more : aemagroupe.fr

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Press contact
Valérie Imparatovimparato@aemagroupe.fr – +33 6 10 24 48 68
Catherine Meddahic.meddahi@agence-influences.fr – +33 6 08 14 49 70

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

P&G Puts Athletes Who Lead with Love Center Stage at Olympic Games Tokyo 2020, Celebrating Their Efforts and Inspiring Positive Action in Others5.8.2021 21:49:00 EEST | Press release

As an Olympic sponsor for the past 10 years, Procter & Gamble’s (NYSE: PG) focus is on celebrating and supporting the unique journeys athletes take on the road to their Olympic dreams, including the causes they champion and the work they do to drive positive change in their communities. In the lead up to the Olympic Games Tokyo 2020, P&G was inspired by the selfless actions of Olympic and Paralympic athletes around the world who stepped up and served others. This led P&G to create the Athletes for Good Fund in partnership with the International Olympic Committee (IOC) and International Paralympic Committee (IPC). Its purpose is to honor and fuel the work of Olympic and Paralympic athletes and hopefuls who lend their time, talent, and resources to charitable causes in the areas of Community Impact, Equality & Inclusion, and Environmental Sustainability. For Tokyo 2020, Athletes for Good Fund provided more than $500,000 in grants to help fuel the efforts of the recipients’ charities of c

Champion® Athleticwear Unveils Second Capsule in Muhammad Ali Collection5.8.2021 20:02:00 EEST | Press release

Champion, makers of authentic athletic apparel since 1919, and Muhammad Ali Enterprises, today dropped the second, limited-edition capsule in Champion’s Muhammad Ali Collection. The capsule’s new designs and fresh colors are fabricated to evoke the ethos of the sports legend during his inspirational gold medal win during the 1960 Games in Rome as an 18-year-old. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210805005624/en/ With details based on the 1960 Games historic location and team uniforms, Champion's Muhammad Ali collection features unique athletic accents, iconic silhouettes, luxe fabrics and voluminous draping. The men’s and women’s apparel includes Reverse Weave® hoodies, quarter-zip pullovers, joggers, shorts, graphic T-shirts, crop tops, bike shorts, hats and a special satin boxing robe. The collection is being distributed via Champion.com and Champion retail stores with distribution in the United States, Europe

Täydennys tarjousasiakirjaan koskien Adapteo Oyj:n hallituksen suosittelemaa julkista käteisostotarjousta Adapteo Oyj:n osakkeenomistajille on julkaistu5.8.2021 19:17:00 EEST | Tiedote

Palace Bidco Oy (”WSIP Bidco”), joka on West Street Global Infrastructure Partners IV, L.P.:n lukuun perustettu ja sen välillisesti kokonaan omistama yksityinen osakeyhtiö, julkisti 17.5.2021 Adapteo Oyj:n (”Adapteo”) hallituksen suositteleman julkisen käteisostotarjouksen Adapteon osakkeenomistajille kaikkien Adapteon osakkeiden hankkimiseksi WSIP Bidcolle (”Ostotarjous”). WSIP Bidco tarjoaa 165 Ruotsin kruunua kustakin Adapteon osakkeesta. Ostotarjousta koskeva tarjousasiakirja julkaistiin 23.6.2021 (”Tarjousasiakirja”). WSIP Bidco on laatinut Tarjousasiakirjaa koskevan täydennysasiakirjan (”Täydennysasiakirja”), joka on julkaistu tänään. Täydennysasiakirja on laadittu liittyen 3.8.2021 julkistettuun Adapteon osavuosiselvitykseen tammi-kesäkuulta 2021, täydentäviin tietoihin koskien euroissa maksettavaa selvitysmaksua niille Adapteon osakkeenomistajille, joiden osakkeet on rekisteröity suoraan Euroclear Finlandissa, sekä Ruotsin arvopaperilautakunnan lausuntoon AMN 2021:39 liittyen G

Moody’s Analytics Earns #2 Overall Ranking in Chartis Research STORM505.8.2021 17:15:00 EEST | Press release

Moody’s Analytics is #2 in the inaugural Chartis Research STORM50 (Statistical Techniques, Optimization frameworks and Risk Models) ranking of the world’s leading providers of quantitative solutions for the financial industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210805005744/en/ Chartis’ STORM50 ranking measures the strength of solutions in quantitative modeling and software, assessing the level of innovation and the quality of the underlying computational infrastructure. The scoring is based on five criteria: breadth and coverage, impact, computational infrastructure, innovation, and strategy. In addition to the #2 ranking overall, Moody’s Analytics placed first in 14 of 55 categories, including Breadth & Coverage, Impact, Strategy, and Innovation, evidencing the depth of the company’s modeling expertise. “The inaugural Chartis Research STORM50 ranking highlights our ability to deliver an integrated view of risk

Ultivue Announces Co-Marketing Agreement with Fluidigm for Biomarker Imaging Solutions for Precision Medicine5.8.2021 16:30:00 EEST | Press release

Ultivue, Inc. and Fluidigm Corporation (Nasdaq:FLDM) today announced a co-marketing agreement in which the companies will offer customers a comprehensive portfolio of workflow solutions for biomarker discovery and drug development. Ultivue, a leader in advancing precision medicine solutions by accelerating tissue biomarker discovery and validation develops unique assays for use in multiplex immunofluorescence imaging and analysis. Its proprietary InSituPlex® technology is designed for fast and comprehensive exploration of biologically-relevant markers combined with same slide-H&E analysis in precious tissue samples. Fluidigm is a leader in high-parameter imaging for the clinical translational research and clinical testing markets. It’s Imaging Mass Cytometry™ (IMC™) technology is designed for highly multiplexed targeted interrogation of tissue sections for 40 or more protein markers in one scan, with distinct non-overlapping signals from element-labeled antibodies detected simultaneous

Andersen Global Strengthens Puerto Rican Coverage with Tax and Advisory Firm5.8.2021 16:30:00 EEST | Press release

Andersen Global adds dimension to its platform in Puerto Rico with the addition of collaborating firm AFS CPA Group LLC (AFS), solidifying its presence in the country with tax and legal coverage. AFS provides tax and advisory services to clients including individuals and small and large businesses, serving a variety of industries such as legal, medical, food and restaurants, apparel, marketing, technology, non-profit and homeowners associations. The firm, established in 2000 by Founder and Managing Partner Antonio Sécola, is based in Gurabo and offers tax, financial, investment and cash management services as well as outsourcing and payroll functions. “As an Arthur Andersen alumnus, I look forward to rejoining the culture and working with like-minded individuals who are committed to serving clients best-in-class solutions,” Antonio said. “Our firm is dedicated to providing the highest quality service, and this collaboration further supplements our ability to deliver seamless solutions

Precision for Medicine and Trialbee Partner to Advance Clinical Trials for Complex Therapies and Speed Shift Toward Precision Medicine5.8.2021 16:00:00 EEST | Press release

Clinical research organization Precision for Medicine and Trialbee, a patient matching and enrollment platform, are addressing complexities in clinical development through a new partnership that will accelerate the future of precision medicine. Trialbee’s advanced analytics will play a critical role in matching patients to trials conducted by Precision for Medicine and extending recruitment to a more diverse, targeted patient community for the development of complex, personalized medicine. The partnership expands Precision for Medicine’s ability to match patients who could benefit from life-saving therapies, especially those who could be a match for trials in oncology, rare and orphan diseases, including cell or gene therapy trials. Trialbee enables accurate and fast enrollment, improving the patient journey and helping to meet patient enrollment timelines. The Precision Site Network, which includes both academic and non-academic sites across North America, Europe, and Australia, can c

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom